Al Ayoub Yuosef, Buzgeia Asma, Almousawi Ghadeer, Mazhar Hassan Raza Ali, Alzouebi B, Gopalan Rajendran C, Assi K H
Eurofins Professional Scientific Services UK Limited, Unit G1 Valiant Way, I54 Business Park, Wolverhampton, WV9 5GB, UK.
School of Pharmacy and Medical Sciences, University of Bradford, Bradford, UK.
J Pharm Sci. 2022 Feb;111(2):395-402. doi: 10.1016/j.xphs.2021.09.042. Epub 2021 Sep 29.
In vitro dissolution testing as a form of quality control has become a necessity in the pharmaceutical industry. As such, the need to establish a method that investigates the in vitro dissolution profile of inhaled products should be taken into account. The prime focus in this study was to examine the in-vitro in-vivo correlation utilising a modified version of the Twin Stage Impinger and to promote an in vitro dissolution model by enhancing the Fine Particle Dose (FPD) collection method for dry powder inhalers. The Twin Impinger was modified by inserting a stainless steel membrane holder disk in the base of the lower chamber. The design, with optimum drug deposition, was adopted for the dissolution study of budesonide and salbutamol. Afterwards, the membrane holder system was placed in the bottom of the dissolution vessel. Phosphate buffer saline (PBS), simulated lung fluid (SLF, Gamble solution) and Phosphate buffer (PB) were used in the study. The paddle dissolution apparatus, containing 300 mL of the medium, was operated at 75 rpm paddle speed. Samples were collected at defined time intervals and analysed using a validated HPLC method. The largest proportion of the budesonide dose was dissolved in PBS compared to PB and SLF. This was due to the presence of surfactant (0.2% w/v polysorbate), which enhances the wettability and the solubility of the poorly soluble drug (budesonide). The similarity factors for PBS and PB were 47.6 and 69.7, respectively, using SLF as a reference, whereas the similarity factor for salbutamol dissolution between PB and SLF was 81.3, suggesting PB is a suitable substitute. Comparison using both the predicted and actual in vivo pharmacokinetics (PK) values of the two drugs, as well as the pattern of their Concentration-Time (c-t) profiles, showed good similarity, which gave an indication of the validity of this in vitro dissolution method.
作为质量控制的一种形式,体外溶出度测试已成为制药行业的一项必要手段。因此,需要考虑建立一种方法来研究吸入产品的体外溶出曲线。本研究的主要重点是利用改良版的双级冲击器研究体外-体内相关性,并通过改进干粉吸入器的细颗粒剂量(FPD)收集方法来推广体外溶出模型。通过在下腔室底部插入一个不锈钢膜支架盘对双冲击器进行了改良。采用具有最佳药物沉积效果的设计用于布地奈德和沙丁胺醇的溶出度研究。之后,将膜支架系统置于溶出容器底部。本研究使用了磷酸盐缓冲盐水(PBS)、模拟肺液(SLF,甘布尔溶液)和磷酸盐缓冲液(PB)。含有300 mL介质的桨板溶出装置以75 rpm的桨板速度运行。在规定的时间间隔收集样品,并使用经过验证的高效液相色谱法进行分析。与PB和SLF相比,布地奈德剂量的最大比例在PBS中溶解。这是由于表面活性剂(0.2% w/v聚山梨酯)的存在,它提高了难溶性药物(布地奈德)的润湿性和溶解度。以SLF为参比,PBS和PB的相似因子分别为47.6和69.7,而PB和SLF之间沙丁胺醇溶出的相似因子为81.3,表明PB是一种合适的替代物。使用两种药物的预测和实际体内药代动力学(PK)值以及它们的浓度-时间(c-t)曲线模式进行比较,显示出良好的相似性,这表明这种体外溶出方法是有效的。